Comparison of an Initial Risk-Based Testing Strategy vs Usual Testing in Stable Symptomatic Patients With Suspected Coronary Artery Disease
Pamela S. Douglas(Duke University), Jane Cao, W. Schuyler Jones(Duke University), Stephen R. Bloom(Imperial College London), Manesh R. Patel(Clinical Research Institute), Eric Yow(Duke University), Sarah Mullen(HeartFlow (United States)), Stuart Pocock(University of London), Daniel B. Mark(Clinical Research Institute), Beth Martinez(Duke University), Björn Redfors(Cardiovascular Research Foundation), Nick Curzen(University Hospital Southampton NHS Foundation Trust), Michael Barry, Robert Pelberg, Christopher M. Kramer(American College of Cardiology), Campbell Rogers(HeartFlow (United States)), Ziad A. Ali, Anthony N. DeMaria, Ori Ben‐Yehuda(University of San Diego), Michael G. Nanna(Yale University), Gregg W. Stone(Cardiovascular Research Foundation), Binita Shah(New York University), David Engel, Ozgu M. Issever, Bernard De Bruyne(Onze Lieve Vrouwziekenhuis Hospital), Yanhong Li, Michelle D. Kelsey(Duke University), Colin Berry(University of Glasgow), Melanie R. Daniels, Whitney Huey(HeartFlow (United States)), Christopher B. Fordyce(University Health Network), Hussein R. Al‐Khalidi(Clinical Research Institute), Gianluca Pontone(Centro Cardiologico Monzino), Kevin J. Anstrom(University of North Carolina at Chapel Hill), Sreekanth Vemulapalli, James E. Udelson(Tufts Medical Center), Shea E. Hogan(University of Colorado Denver), Robert A. Byrne(Okayama University Hospital), Robert W. Yeh(Beth Israel Deaconess Medical Center), Andrew M. Kahn(University of California San Diego), Marc P. Bonaca(University of Colorado Anschutz Medical Campus), Pál Maurovich‐Horvat(Semmelweis University), Jonathon Leipsic(University of British Columbia), Patricia A. Cowper(Duke University), V. Marinescu(Edward Hospital), Derek Chow, David Buck, Weibing Xing, John P. Greenwood(University of Leeds)
Cited by 97
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Abdominal Visceral and Subcutaneous Adipose Tissue Compartments
|Circulation|2007|2.9k